These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

699 related articles for article (PubMed ID: 33268887)

  • 1. Immunological mechanisms and therapeutic targets of fatty liver diseases.
    Wang H; Mehal W; Nagy LE; Rotman Y
    Cell Mol Immunol; 2021 Jan; 18(1):73-91. PubMed ID: 33268887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune cells and their derived microRNA-enriched extracellular vesicles in nonalcoholic fatty liver diseases: Novel therapeutic targets.
    Yang L; Hao Y; Boeckmans J; Rodrigues RM; He Y
    Pharmacol Ther; 2023 Mar; 243():108353. PubMed ID: 36738973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extracellular Vesicles as Inflammatory Drivers in NAFLD.
    Srinivas AN; Suresh D; Santhekadur PK; Suvarna D; Kumar DP
    Front Immunol; 2020; 11():627424. PubMed ID: 33603757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrin β
    Guo Q; Furuta K; Lucien F; Gutierrez Sanchez LH; Hirsova P; Krishnan A; Kabashima A; Pavelko KD; Madden B; Alhuwaish H; Gao Y; Revzin A; Ibrahim SH
    J Hepatol; 2019 Dec; 71(6):1193-1205. PubMed ID: 31433301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNAs in the Pathogenesis of Nonalcoholic Fatty Liver Disease.
    Fang Z; Dou G; Wang L
    Int J Biol Sci; 2021; 17(7):1851-1863. PubMed ID: 33994867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extracellular Vesicles in NAFLD/ALD: From Pathobiology to Therapy.
    Hernández A; Arab JP; Reyes D; Lapitz A; Moshage H; Bañales JM; Arrese M
    Cells; 2020 Mar; 9(4):. PubMed ID: 32231001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of immune mechanisms in alcoholic and nonalcoholic steatohepatitis: a 2015 update.
    Sutti S; Bruzzì S; Albano E
    Expert Rev Gastroenterol Hepatol; 2016; 10(2):243-53. PubMed ID: 26634783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inflammatory pathways in alcoholic steatohepatitis.
    Gao B; Ahmad MF; Nagy LE; Tsukamoto H
    J Hepatol; 2019 Feb; 70(2):249-259. PubMed ID: 30658726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of immune cells in metabolism-related liver inflammation and development of non-alcoholic steatohepatitis (NASH).
    Nati M; Haddad D; Birkenfeld AL; Koch CA; Chavakis T; Chatzigeorgiou A
    Rev Endocr Metab Disord; 2016 Mar; 17(1):29-39. PubMed ID: 26847547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatocyte and immune cell crosstalk in non-alcoholic fatty liver disease.
    Carranza-Trejo AM; Vetvicka V; Vistejnova L; Kralickova M; Montufar EB
    Expert Rev Gastroenterol Hepatol; 2021 Jul; 15(7):783-796. PubMed ID: 33557653
    [No Abstract]   [Full Text] [Related]  

  • 11. Extracellular vesicles in fatty liver disease and steatohepatitis: Role as biomarkers and therapeutic targets.
    Eguchi A; Iwasa M; Nakagawa H
    Liver Int; 2023 Feb; 43(2):292-298. PubMed ID: 36462157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Macrophages as Key Players during Adipose Tissue-Liver Crosstalk in Nonalcoholic Fatty Liver Disease.
    Korf H; Boesch M; Meelberghs L; van der Merwe S
    Semin Liver Dis; 2019 Jul; 39(3):291-300. PubMed ID: 31041786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetics: An emerging field in the pathogenesis of nonalcoholic fatty liver disease.
    Ashraf NU; Altaf M
    Mutat Res Rev Mutat Res; 2018; 778():1-12. PubMed ID: 30454678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alcohol, microbiome, life style influence alcohol and non-alcoholic organ damage.
    Neuman MG; French SW; Zakhari S; Malnick S; Seitz HK; Cohen LB; Salaspuro M; Voinea-Griffin A; Barasch A; Kirpich IA; Thomes PG; Schrum LW; Donohue TM; Kharbanda KK; Cruz M; Opris M
    Exp Mol Pathol; 2017 Feb; 102(1):162-180. PubMed ID: 28077318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extracellular vesicles in non-alcoholic and alcoholic fatty liver diseases.
    Eguchi A; Feldstein AE
    Liver Res; 2018 Mar; 2(1):30-34. PubMed ID: 30345152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extracellular Vesicles in the Development of the Non-Alcoholic Fatty Liver Disease: An Update.
    Dorairaj V; Sulaiman SA; Abu N; Abdul Murad NA
    Biomolecules; 2020 Oct; 10(11):. PubMed ID: 33143043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic Inflammation in Non-Alcoholic Steatohepatitis: Molecular Mechanisms and Therapeutic Strategies.
    Luci C; Bourinet M; Leclère PS; Anty R; Gual P
    Front Endocrinol (Lausanne); 2020; 11():597648. PubMed ID: 33384662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intracellular and extracellular miRNome deregulation in cellular models of NAFLD or NASH: Clinical implications.
    Di Mauro S; Ragusa M; Urbano F; Filippello A; Di Pino A; Scamporrino A; Pulvirenti A; Ferro A; Rabuazzo AM; Purrello M; Purrello F; Piro S
    Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1129-1139. PubMed ID: 27756518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Th17 involvement in nonalcoholic fatty liver disease progression to non-alcoholic steatohepatitis.
    Chackelevicius CM; Gambaro SE; Tiribelli C; Rosso N
    World J Gastroenterol; 2016 Nov; 22(41):9096-9103. PubMed ID: 27895397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutrophil-to-hepatocyte communication via LDLR-dependent miR-223-enriched extracellular vesicle transfer ameliorates nonalcoholic steatohepatitis.
    He Y; Rodrigues RM; Wang X; Seo W; Ma J; Hwang S; Fu Y; Trojnár E; Mátyás C; Zhao S; Ren R; Feng D; Pacher P; Kunos G; Gao B
    J Clin Invest; 2021 Feb; 131(3):. PubMed ID: 33301423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.